BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Down 5.7% in December

BriaCell Therapeutics Corp. (NASDAQ:BCTXGet Rating) was the recipient of a large decline in short interest in the month of December. As of December 30th, there was short interest totalling 1,320,000 shares, a decline of 5.7% from the December 15th total of 1,400,000 shares. Based on an average daily trading volume, of 236,800 shares, the days-to-cover ratio is presently 5.6 days. Approximately 12.7% of the company’s shares are sold short.

BriaCell Therapeutics Price Performance

NASDAQ:BCTX opened at $7.04 on Monday. The firm has a market cap of $109.25 million, a price-to-earnings ratio of -4.29 and a beta of 1.01. The firm’s fifty day moving average price is $5.59 and its 200 day moving average price is $6.16. BriaCell Therapeutics has a 1-year low of $4.06 and a 1-year high of $12.09.

BriaCell Therapeutics (NASDAQ:BCTXGet Rating) last released its quarterly earnings data on Thursday, October 27th. The company reported ($1.01) EPS for the quarter. As a group, analysts expect that BriaCell Therapeutics will post -1.44 earnings per share for the current fiscal year.

Insider Activity at BriaCell Therapeutics

In related news, Chairman Jamieson Bondarenko purchased 28,000 shares of the business’s stock in a transaction on Wednesday, December 28th. The shares were bought at an average price of $4.58 per share, for a total transaction of $128,240.00. Following the acquisition, the chairman now directly owns 169,856 shares in the company, valued at $777,940.48. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 19.02% of the company’s stock.

Institutional Trading of BriaCell Therapeutics

Large investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in shares of BriaCell Therapeutics during the 2nd quarter valued at about $60,000. Apollon Wealth Management LLC boosted its holdings in shares of BriaCell Therapeutics by 14.4% in the second quarter. Apollon Wealth Management LLC now owns 15,900 shares of the company’s stock valued at $92,000 after acquiring an additional 2,000 shares in the last quarter. Wasatch Advisors Inc. bought a new position in shares of BriaCell Therapeutics in the first quarter valued at approximately $2,481,000. Lynwood Capital Management Inc. lifted its position in shares of BriaCell Therapeutics by 94.8% in the 3rd quarter. Lynwood Capital Management Inc. now owns 1,198,000 shares of the company’s stock valued at $6,733,000 after acquiring an additional 583,000 shares in the last quarter. Finally, K.J. Harrison & Partners Inc raised its stake in BriaCell Therapeutics by 18.9% during the 2nd quarter. K.J. Harrison & Partners Inc now owns 1,607,027 shares of the company’s stock valued at $9,188,000 after purchasing an additional 255,245 shares during the period. Institutional investors and hedge funds own 16.34% of the company’s stock.

About BriaCell Therapeutics

(Get Rating)

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab.

Featured Stories

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with's FREE daily email newsletter.